Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab
This item is licensed under:Creative Commons Attribution-NonCommercial 4.0 International
Title: | Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab |
Authors: | Shibayama, Yui Browse this author | Kameda, Hiraku Browse this author | Ota, Shoichiro Browse this author | Tsuchida, Kazuhisa Browse this author | Cho, Kyu Yong Browse this author | Nakamura, Akinobu Browse this author →KAKEN DB | Miyoshi, Hideaki Browse this author →KAKEN DB | Atsumi, Tatsuya Browse this author →KAKEN DB |
Keywords: | Anti-programmed death-ligand 1 antibody | Fulminant type 1 diabetes | Immune-related adverse events |
Issue Date: | Sep-2019 |
Publisher: | John Wiley & Sons |
Journal Title: | Journal of diabetes investigation |
Volume: | 10 |
Issue: | 5 |
Start Page: | 1385 |
End Page: | 1387 |
Publisher DOI: | 10.1111/jdi.13022 |
Abstract: | With the expansive use of immune checkpoint inhibitors, the frequency of immune-related adverse events, including autoimmune type 1 diabetes, has been exponentially increased. The anti-programmed death-ligand 1 antibody, avelumab, has recently been approved for metastatic Merkel cell carcinoma therapy. Here, we report a patient that developed fulminant type 1 diabetes during avelumab treatment. An 81-year-old woman with no history of diabetes received avelumab for metastatic Merkel cell carcinoma. Elevated plasma glucose level (483 mg/dL), hemoglobin A1c level (7.5%) and ketosis were observed after 10 courses of avelumab without any symptoms related to hyperglycemia. As the laboratory tests showed insulin depletion, we diagnosed her with fulminant type 1 diabetes induced by avelumab. This is the first reported case of avelumab-induced type 1 diabetes, illustrating the necessity for close monitoring of glycemic control during avelumab therapy, as well as other immune checkpoint inhibitors. |
Rights: | https://creativecommons.org/licenses/by-nc/4.0/ |
Type: | article |
URI: | http://hdl.handle.net/2115/75841 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|